Jeil Pharma Holdings Inc (002620.KS)
KRW 7990.0
(-3.5%)
KRW 7990.0
(-3.5%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 477.81 Billion KRW | 7.16% |
| 2022 | 445.88 Billion KRW | 13.71% |
| 2021 | 392.1 Billion KRW | 1.03% |
| 2020 | 388.11 Billion KRW | 6.79% |
| 2019 | 363.43 Billion KRW | 9.96% |
| 2018 | 330.5 Billion KRW | 1117.39% |
| 2017 | 27.14 Billion KRW | -88.68% |
| 2016 | 239.9 Billion KRW | 17.73% |
| 2015 | 203.77 Billion KRW | 16.88% |
| 2014 | 174.35 Billion KRW | 10.01% |
| 2013 | 158.49 Billion KRW | 6.12% |
| 2012 | 149.35 Billion KRW | -2.21% |
| 2011 | 152.73 Billion KRW | 11.34% |
| 2010 | 137.18 Billion KRW | 28.95% |
| 2009 | 106.38 Billion KRW | -5.0% |
| 2008 | 111.98 Billion KRW | -2.36% |
| 2007 | 114.68 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 444.86 Billion KRW | -7.43% |
| 2024 Q1 | 480.57 Billion KRW | 0.58% |
| 2023 Q2 | 465.01 Billion KRW | 2.27% |
| 2023 Q1 | 454.71 Billion KRW | 1.98% |
| 2023 FY | 477.81 Billion KRW | 7.16% |
| 2023 Q4 | 477.81 Billion KRW | -1.38% |
| 2023 Q3 | 484.5 Billion KRW | 4.19% |
| 2022 Q2 | 413.23 Billion KRW | 1.97% |
| 2022 Q1 | 405.25 Billion KRW | 3.35% |
| 2022 FY | 445.88 Billion KRW | 13.71% |
| 2022 Q4 | 445.88 Billion KRW | 4.57% |
| 2022 Q3 | 426.39 Billion KRW | 3.19% |
| 2021 Q3 | 394.74 Billion KRW | 2.29% |
| 2021 Q4 | 392.1 Billion KRW | -0.67% |
| 2021 FY | 392.1 Billion KRW | 1.03% |
| 2021 Q1 | 382.52 Billion KRW | -1.44% |
| 2021 Q2 | 385.92 Billion KRW | 0.89% |
| 2020 Q4 | 388.11 Billion KRW | 0.65% |
| 2020 Q2 | 380.29 Billion KRW | 6.15% |
| 2020 Q3 | 385.6 Billion KRW | 1.39% |
| 2020 FY | 388.11 Billion KRW | 6.79% |
| 2020 Q1 | 358.28 Billion KRW | -1.42% |
| 2019 Q2 | 316.84 Billion KRW | 0.56% |
| 2019 Q4 | 363.43 Billion KRW | 20.28% |
| 2019 Q1 | 315.08 Billion KRW | -4.67% |
| 2019 Q3 | 302.16 Billion KRW | -4.63% |
| 2019 FY | 363.43 Billion KRW | 9.96% |
| 2018 Q2 | 90 Billion KRW | 210.26% |
| 2018 Q3 | 99.46 Billion KRW | 10.51% |
| 2018 FY | 330.5 Billion KRW | 1117.39% |
| 2018 Q1 | 29 Billion KRW | 6.85% |
| 2018 Q4 | 330.5 Billion KRW | 232.28% |
| 2017 Q1 | 234.06 Billion KRW | -2.44% |
| 2017 Q2 | 27.38 Billion KRW | -88.3% |
| 2017 FY | 27.14 Billion KRW | -88.68% |
| 2017 Q3 | 29.13 Billion KRW | 6.41% |
| 2017 Q4 | 27.14 Billion KRW | -6.83% |
| 2016 FY | 239.9 Billion KRW | 17.73% |
| 2016 Q4 | 239.9 Billion KRW | 0.0% |
| 2015 Q2 | 191.83 Billion KRW | -4.75% |
| 2015 FY | 203.77 Billion KRW | 16.88% |
| 2015 Q3 | 194.32 Billion KRW | 1.3% |
| 2015 Q1 | 201.41 Billion KRW | 15.52% |
| 2014 Q1 | 160.56 Billion KRW | 1.31% |
| 2014 Q2 | 168.45 Billion KRW | 4.91% |
| 2014 Q3 | 179.11 Billion KRW | 6.33% |
| 2014 Q4 | 174.35 Billion KRW | -2.66% |
| 2014 FY | 174.35 Billion KRW | 10.01% |
| 2013 Q3 | 159.06 Billion KRW | 0.5% |
| 2013 Q4 | 158.49 Billion KRW | -0.36% |
| 2013 Q2 | 158.28 Billion KRW | 10.62% |
| 2013 Q1 | 143.09 Billion KRW | -4.2% |
| 2013 FY | 158.49 Billion KRW | 6.12% |
| 2012 Q3 | 160.99 Billion KRW | -1.64% |
| 2012 Q2 | 163.67 Billion KRW | 3.71% |
| 2012 Q1 | 157.81 Billion KRW | 3.33% |
| 2012 FY | 149.35 Billion KRW | -2.21% |
| 2012 Q4 | 149.35 Billion KRW | -7.23% |
| 2011 FY | 152.73 Billion KRW | 11.34% |
| 2011 Q4 | 152.73 Billion KRW | 4.12% |
| 2011 Q3 | 146.69 Billion KRW | 0.02% |
| 2011 Q2 | 146.66 Billion KRW | -6.59% |
| 2011 Q1 | 157 Billion KRW | 14.45% |
| 2010 Q1 | 139.89 Billion KRW | 31.5% |
| 2010 Q2 | 144.63 Billion KRW | 3.39% |
| 2010 FY | 137.18 Billion KRW | 28.95% |
| 2010 Q4 | 137.18 Billion KRW | 0.03% |
| 2010 Q3 | 137.14 Billion KRW | -5.18% |
| 2009 Q3 | 111.7 Billion KRW | -2.78% |
| 2009 Q2 | 114.89 Billion KRW | 7.59% |
| 2009 Q1 | 106.78 Billion KRW | -4.64% |
| 2009 FY | 106.38 Billion KRW | -5.0% |
| 2009 Q4 | 106.38 Billion KRW | -4.76% |
| 2008 Q1 | 115.39 Billion KRW | 0.62% |
| 2008 Q2 | 113.98 Billion KRW | -1.23% |
| 2008 Q4 | 111.98 Billion KRW | 3.08% |
| 2008 Q3 | 108.64 Billion KRW | -4.69% |
| 2008 FY | 111.98 Billion KRW | -2.36% |
| 2007 Q3 | 115.6 Billion KRW | -0.32% |
| 2007 FY | 114.68 Billion KRW | 0.0% |
| 2007 Q2 | 115.97 Billion KRW | 4.62% |
| 2007 Q4 | 114.68 Billion KRW | -0.79% |
| 2007 Q1 | 110.85 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -513.696% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 48.611% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 32.426% |
| HANDOK Inc. | 449.7 Billion KRW | -6.249% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -457.732% |
| Yuhan Corporation | 712.33 Billion KRW | 32.924% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 24.386% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -2906.143% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 43.907% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -792.627% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -132.087% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -535.632% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | -223.295% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -578.696% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -513.696% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -1211.361% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | -90.248% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | -116.493% |
| JW Holdings Corporation | 827.51 Billion KRW | 42.259% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | -9.34% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 18.573% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -25.873% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -502.524% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -582.903% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | -96.749% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | -44.662% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -513.696% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 2.491% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 44.313% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -25.873% |
| Yuhan Corporation | 712.33 Billion KRW | 32.924% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | -248.847% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 7.521% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -25.873% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | -209.19% |
| Korea United Pharm Inc. | 89.96 Billion KRW | -431.106% |
| CKD Bio Corp. | 170.76 Billion KRW | -179.813% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | -96.038% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | -203.07% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -1010.693% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -502.524% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 24.459% |
| Boryung Corporation | 373.1 Billion KRW | -28.062% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | -129.499% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -132.087% |
| JW Lifescience Corporation | 96.44 Billion KRW | -395.432% |